930 related articles for article (PubMed ID: 15328169)
21. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
22. Activity and toxicity of intramuscular 1000 iu/m
Sidhu J; Masurekar AN; Gogoi MP; Fong C; Ioannou T; Lodhi T; Parker C; Liu J; Kirkwood AA; Moorman AV; Das K; Goulden NJ; Vora A; Saha V; Krishnan S
Br J Haematol; 2022 Jul; 198(1):142-150. PubMed ID: 35348200
[TBL] [Abstract][Full Text] [Related]
23. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
24. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
25. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
26. Asparaginase activities during intensified treatment with pegylated
Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of native Escherichia coli asparaginase.
Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
[TBL] [Abstract][Full Text] [Related]
29. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Avramis VI; Tiwari PN
Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study.
Würthwein G; Lanvers-Kaminsky C; Gerss J; Möricke A; Zimmermann M; Stary J; Smisek P; Attarbaschi A; Nath C; Zucchetti M; Rizzari C; Schrappe M; Boos J;
Ther Drug Monit; 2020 Jun; 42(3):435-444. PubMed ID: 32022785
[TBL] [Abstract][Full Text] [Related]
31. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL.
Appel IM; Pinheiro JP; den Boer ML; Lanvers C; Reniers NC; Boos J; Pieters R
Leukemia; 2003 Nov; 17(11):2254-6. PubMed ID: 14523472
[No Abstract] [Full Text] [Related]
32. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
Avramis VI; Sencer S; Periclou AP; Sather H; Bostrom BC; Cohen LJ; Ettinger AG; Ettinger LJ; Franklin J; Gaynon PS; Hilden JM; Lange B; Majlessipour F; Mathew P; Needle M; Neglia J; Reaman G; Holcenberg JS; Stork L
Blood; 2002 Mar; 99(6):1986-94. PubMed ID: 11877270
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
[TBL] [Abstract][Full Text] [Related]
34. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
[TBL] [Abstract][Full Text] [Related]
36. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).
Grigoryan RS; Panosyan EH; Seibel NL; Gaynon PS; Avramis IA; Avramis VI
In Vivo; 2004; 18(2):107-12. PubMed ID: 15113036
[TBL] [Abstract][Full Text] [Related]
37. Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.
Würthwein G; Lanvers-Kaminsky C; Siebel C; Gerß J; Möricke A; Zimmermann M; Stary J; Smisek P; Schrappe M; Rizzari C; Zucchetti M; Hempel G; Wicha SG; Boos J;
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):289-300. PubMed ID: 33595793
[TBL] [Abstract][Full Text] [Related]
38. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
Rizzari C; Lanvers-Kaminsky C; Valsecchi MG; Ballerini A; Matteo C; Gerss J; Wuerthwein G; Silvestri D; Colombini A; Conter V; Biondi A; Schrappe M; Moericke A; Zimmermann M; von Stackelberg A; Linderkamp C; Frühwald MC; Legien S; Attarbaschi A; Reismüller B; Kasper D; Smisek P; Stary J; Vinti L; Barisone E; Parasole R; Micalizzi C; Zucchetti M; Boos J
Haematologica; 2019 Sep; 104(9):1812-1821. PubMed ID: 30705097
[TBL] [Abstract][Full Text] [Related]
39. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.
Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
Cancer Chemother Pharmacol; 1993; 32(4):310-4. PubMed ID: 8324873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
